These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 10468947)

  • 1. Dose titration and patient selection increases the efficacy of GH replacement in severely GH deficient adults.
    Murray RD; Skillicorn CJ; Howell SJ; Lissett CA; Rahim A; Shalet SM
    Clin Endocrinol (Oxf); 1999 Jun; 50(6):749-57. PubMed ID: 10468947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influences on quality of life in GH deficient adults and their effect on response to treatment.
    Murray RD; Skillicorn CJ; Howell SJ; Lissett CA; Rahim A; Smethurst LE; Shalet SM
    Clin Endocrinol (Oxf); 1999 Nov; 51(5):565-73. PubMed ID: 10594517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body composition and quality of life in adults with growth hormone deficiency; effects of low-dose growth hormone replacement.
    Ahmad AM; Hopkins MT; Thomas J; Ibrahim H; Fraser WD; Vora JP
    Clin Endocrinol (Oxf); 2001 Jun; 54(6):709-17. PubMed ID: 11422104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of gender on the short and long-term effects of growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults: a 5-year study.
    Drake WM; Rodríguez-Arnao J; Weaver JU; James IT; Coyte D; Spector TD; Besser GM; Monson JP
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):525-32. PubMed ID: 11318789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spinal irradiation impairs the osteo-anabolic effects of low-dose GH replacement in adults with childhood-onset GH deficiency.
    Murray RD; Adams JE; Smethurst LE; Shalet SM
    Clin Endocrinol (Oxf); 2002 Feb; 56(2):169-74. PubMed ID: 11874407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study.
    Florakis D; Hung V; Kaltsas G; Coyte D; Jenkins PJ; Chew SL; Grossman AB; Besser GM; Monson JP
    Clin Endocrinol (Oxf); 2000 Oct; 53(4):453-9. PubMed ID: 11012570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seven years of growth hormone (GH) replacement improves quality of life in hypopituitary patients with adult-onset GH deficiency.
    Elbornsson M; Horvath A; Götherström G; Bengtsson BÅ; Johannsson G; Svensson J
    Eur J Endocrinol; 2017 Feb; 176(2):99-109. PubMed ID: 27803031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency.
    Götherström G; Bengtsson BA; Bosaeus I; Johannsson G; Svensson J
    Eur J Endocrinol; 2007 Jan; 156(1):55-64. PubMed ID: 17218726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone deficiency and replacement in elderly hypopituitary adults. KIMS Study Group and the KIMS International Board. Pharmacia and Upjohn International Metabolic Database.
    Monson JP; Abs R; Bengtsson BA; Bennmarker H; Feldt-Rasmussen U; Hernberg-Stâhl E; Thorén M; Westberg B; Wilton P; Wüster C
    Clin Endocrinol (Oxf); 2000 Sep; 53(3):281-9. PubMed ID: 10971444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interdependence of lean body mass and total body water, but not quality of life measures, during low dose GH replacement in GH-deficient adults.
    Mukherjee A; Adams JE; Smethurst L; Shalet SM
    Eur J Endocrinol; 2005 Nov; 153(5):661-8. PubMed ID: 16260424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults.
    Gilchrist FJ; Murray RD; Shalet SM
    Clin Endocrinol (Oxf); 2002 Sep; 57(3):363-70. PubMed ID: 12201829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The characteristics of quality of life impairment in adult growth hormone (GH)-deficient survivors of cancer and their response to GH replacement therapy.
    Mukherjee A; Tolhurst-Cleaver S; Ryder WD; Smethurst L; Shalet SM
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1542-9. PubMed ID: 15613427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GH-deficient survivors of childhood cancer: GH replacement during adult life.
    Murray RD; Darzy KH; Gleeson HK; Shalet SM
    J Clin Endocrinol Metab; 2002 Jan; 87(1):129-35. PubMed ID: 11788635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elderly people with hypothalamic-pituitary disease and growth hormone deficiency: lipid profiles, body composition and quality of life compared with control subjects.
    Li Voon Chong JS; Benbow S; Foy P; Wallymahmed ME; Wile D; MacFarlane IA
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):551-9. PubMed ID: 11106915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A low individualized GH dose in young patients with childhood onset GH deficiency normalized serum IGF-I without significant deterioration in glucose tolerance.
    Bülow B; Erfurth EM
    Clin Endocrinol (Oxf); 1999 Jan; 50(1):45-55. PubMed ID: 10341855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults.
    Cuneo RC; Judd S; Wallace JD; Perry-Keene D; Burger H; Lim-Tio S; Strauss B; Stockigt J; Topliss D; Alford F; Hew L; Bode H; Conway A; Handelsman D; Dunn S; Boyages S; Cheung NW; Hurley D
    J Clin Endocrinol Metab; 1998 Jan; 83(1):107-16. PubMed ID: 9435425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three weekly injections (TWI) of low-dose growth hormone (GH) restore low normal circulating IGF-I concentrations and reverse cardiac abnormalities associated with adult onset GH deficiency (GHD).
    Pincelli AI; Bragato R; Scacchi M; Branzi G; Osculati G; Viarengo R; Leonetti G; Cavagnini F
    J Endocrinol Invest; 2003 May; 26(5):420-8. PubMed ID: 12906369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-treatment IGF-I level is the major determinant of GH dosage in adult GH deficiency.
    Murray RD; Howell SJ; Lissett CA; Shalet SM
    Clin Endocrinol (Oxf); 2000 May; 52(5):537-42. PubMed ID: 10792331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy.
    Thorén M; Hilding A; Brismar T; Magnusson P; Degerblad M; Larsson L; Sääf M; Baylink DJ; Mohan S
    J Bone Miner Res; 1998 May; 13(5):891-9. PubMed ID: 9610754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of quality of life in adults receiving long-term growth hormone replacement compared to control subjects.
    Malik IA; Foy P; Wallymahmed M; Wilding JP; MacFarlane IA
    Clin Endocrinol (Oxf); 2003 Jul; 59(1):75-81. PubMed ID: 12807507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.